Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed T(h) cells

International Immunology

Volumn 10, Issue 10, 1998, Pages 1397-1406

  Cheng, Ting Ying ^a   Wu, June Tai ^a   Lin, Rong Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Immunogenicity; Immunotherapy; T(h) cell; Tumor immunity

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN CELL; IMMUNOGENICITY; LEUKEMIA CELL LINE; LEUKEMIA P 388; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR RESISTANCE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; FREUND'S ADJUVANT; IMMUNITY, CELLULAR; MICE; MICE, INBRED DBA; OVALBUMIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED;

EID: 0031714865     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/10.10.1397     Document Type: Article

References (42)

1. Boon, T. 1992. Toward a genetic analysis of tumor rejection antigens. Adv. Cancer Res. 58:177.
2. Greenberg, P. D. 1991. Adoptive T cells therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
3. Melief, C. J. M. 1992. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58:143.
4. Elliott, B. E., Carlow, D. A., Rodrick, A. M. and Wade, A. 1989. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53:181.
5. Chen, L., Linsley, P. S. and Hellström, K. E. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
6. June, C. H., Bluestone, J. A., Nadler, M. L. and Thompson, C. B. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321
7. Sulitzeanu, D. 1993. Immunosuppressive factors in human cancer. Adv. Cancer Res. 60:247.
8. Kern, D. E., Klarnet, J. P., Jensen, M. C. V. and Greenberg, P. D. 1986. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol, 136:4303.
9. Chen, P. W. and Ananthaswamy, H. N. 1993. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol. 151:244.
10. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J. and Glimcher, L. H. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl Acad. Sci. USA 90:5687.
11. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181:619.
12. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153:421.
13. Pardoll, M. D. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.
14. Colombo, M. P. and Forni, G. 1994. Cytokine gene transfer in tumor inhibition and tumor therapy, where are we now. Immonol. Today 15:48.
15. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol Methods 145:185.
16. Ostrand-Rosenberg, S., Thakur, A. and Clements V 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144:4068.
17. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791.
18. Townsend, S. E., Su, F. W., Atherton, J. M. and Allison, J. P. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477
19. Mitchison, N. A. 1970. Immunologic approach to cancer. Transplant. Proc. 2:92.
20. d). Cancer Res. 47:3136.
21. Fearon, E. R., Itaya, T., Hunt, B., vogelstein, B. and Frost, P. 1988. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 48:2975.
22. Hosakawa, M., Okayasu, T., Ikeda, K., Katoh, H., Suzuki, Y. and Kobayashi, H. 1983. Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells. Cancer Res. 43:2301.
23. Shimizu, Y., Fujiwara, H., Ueda, S., Wakamiya, N., Kato, S. and Hamaoka, T. 1984. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells. Eur. J. Immunol. 14:839
24. Okayasu, T, Hosokawa, M., Tanabe, T. and Kobayashi, H. 1986. The active immunotherapy of a 3-methylcholanthrene-induced rat tumor with Friend virus-infected (xenogenized) tumor cells. Jpn. J. Cancer Res. 77:817.
25. Ohno, R., Kodera, Y, Ogura, M. and Yamada, H. 1984. Induction of transplantation resistance to murine L1210 leukemia cells in BCG-primed mice by immunization with tuberculin protein-coupled L1210 cells. Jpn. J. Cancer Res. 75:187.
26. Lachmann, P. J. and Sikora, K. 1978. Coupling and PPD to tumor cells enhances their antigenicity in BCG-primed mice. Nature 271:463.
27. Takatsu, R., Hamaoka, T., Tominaga, A. and Kanamasa, Y. 1980. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD coupled syngeneic tumor cells. J. Immunol. 125:2367.
28. Sano, H., Kosugi, A., Sano, S., Fugiwara, H. and Hamaoka, T. 1987. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity. Cancer Immunol. Immunother. 25:180.
29. Shima, J., Yoshioka, T., Nakajima, H., Fujiwara, H. and Hamaoka, T. 1988. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity. Cancer Immunol. Immunother. 26:43.
30. Forni, G., Fujiwara, H., Martino, F., Hamaoka, T., Jemma, C., Caretto, P. and Giovarelli, M. 1988. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metast. Rev. 7:289.
31. Fujiwara, H., Moriyama, Y., Suda, T., Tsuchida, T., Shearer, G. M. and Hamaoka, T. 1984. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression. J. Immunol. 132:1571.
32. Fujiwara, H., Hamaoka, T., Shearer, G. M., Yamamoto, H. and Terry, W. D. 1980. The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes. J. Immunol. 124:863.
33. Geiger, B., Rosen, D. and Berke, G. 1994. Spatial relationships of microtubule-organizing centers and the contact area of cytotoxic T lymphocytes and target cells. J. Cell Biol. 95:137.
34. Poo, W. J., Conrad, L. and Janeway, C. A., Jr. 1988. Receptor-directed focusing of lymphokine release by helper T cells. Nature 332:378.
35. Janeway, C. A., Jr, Bottomly, K., Horowitz, J., Kaye, J., Jone, B. and Tite, J. 1985. Modes of cell:cell communicat on in the immune system. J. immunol 135:739.
36. Kupfer, A., Swain, S. L, Janeway, C. A., Jr and Singer, S. J. 1986. The specific direct interaction of helper T cells and antigen-presenting B cells. Proc. Natl Acad. Sci. USA 83:6080.
37. Sanders, M. E., Makgoba, M. W. and Shaw, S. 1988. Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. Immunol. Today 9:195.
38. + T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J. Immunol. 148:1993.
39. Byrne, J. A., Butler, J. L. and Cooper, M. D. 1988. Differential activation requirements for virgin and memory T cells. J. Immunol. 141:3249.
40. Croft, M., Bradley, L. M. and Swain, L. 1994. Naive versus memory CD4 T cells response to antigen: memory cells are less dependent on accessory cell costimulation and can response to many antigen-presenting cell types including resting B cells. J. Immunol. 152:2675.
41. Rosa, F., Hatat, D., Abadie, A., Wallach, D., Revel, M. and Fellous, M. 1983. Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. EMBO J. 2:1585.
42. Collins, T., Korman. A. J., Wake, C. I, Boss, J. M., Kappes, D. J., Fiers, W., Ault, K. A., Gimbrone, M. A., Jr and Strominger, J. L. 1984. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc. Natl Acad. Sci. USA 81:4917.